PTGX — Protagonist Therapeutics, Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1377121 ·
Last close
$141.86
Market Cap
$9.18B
52W High
$160.81
52W Low
$62.24
ADV30
611,180
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 213,475,000 | — | 158,766,000 | 162,849,000 | 885,544,000 | 420,078,000 | 44,001,000 |
| Mar 2026 | 56,368,000 | — | -3,648,000 | 3,783,000 | 697,459,000 | 193,712,000 | 41,986,000 |
| Dec 2025 | 7,437,000 | — | -50,355,000 | -44,384,000 | 668,188,000 | 128,390,000 | 53,481,000 |
| Sep 2025 | 4,712,000 | — | -46,421,000 | -39,339,000 | 701,688,000 | 113,713,000 | 56,251,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$131,197,000
Investing CF
$78,722,000
Financing CF
$41,613,000
CapEx
$-615,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.03
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-304,039,000
Inventory
—
Receivables
$19,642,000
ST Investments
$362,498,000
EBIT TTM
$58,342,000
Pretax Income TTM
$84,338,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$281,992,000
EBITDA
$59,883,000
Free Cash Flow
$96,145,752
Enterprise Value
$8,815,113,216
Total Cash
$782,576,000
Total Debt
$9,216,000
Shares Out
64,708,285
Trailing EPS
$1.04
Book Value
$13.01
ROE
11.0%
ROA
4.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,016,000 | -158,127,000 | -130,149,000 | 668,188,000 | 53,481,000 | 614,707,000 | 57,671,000 |
| Dec 2024 | 434,433,000 | 252,843,000 | 275,188,000 | 744,725,000 | 69,430,000 | 675,295,000 | 184,152,000 |
| Dec 2023 | 60,000,000 | -93,652,000 | -78,955,000 | 357,951,000 | 21,274,000 | 336,677,000 | -70,236,000 |
| Dec 2022 | 26,581,000 | -131,373,000 | -127,393,000 | 247,928,000 | 32,320,000 | 215,608,000 | -108,137,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-7,084,000
OpCashFlow TTM
$0
Assets (Latest)
$93,990,000
Forward EPS
$-0.20
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $100.00 · spot: $141.86 · call volume: 88 · put volume: 82
Expected Move to 2026-10-16:
±$13.40
(9.45%) —
implied range
$128.46 –
$155.26
· ATM straddle on $140.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $9.31B | $65.92 | — |
| CYTK | CYTOKINETICS INC | $8.99B | $64.66 | — |
| TGTX | TG THERAPEUTICS, INC. | $8.79B | $57.43 | — |
| RDY | DR REDDYS LABORATORIES LTD | $10.20B | $12.25 | — |
| AXSM | Axsome Therapeutics, Inc. | $10.22B | $195.09 | — |
News headlines (Yahoo Finance, 1h cache)
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
2026-09-08 20:05 · Yahoo
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
2026-09-06 12:55 · Yahoo
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
2026-09-04 16:14 · Yahoo
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones
2026-09-01 12:14 · Yahoo
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call
2026-09-01 08:13 · Yahoo
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
2026-08-31 18:02 · Yahoo
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-08-18 20:05 · Yahoo
FDA OKs Takeda, Protagonist drug for rare blood cancer
2026-08-31 12:13 · Yahoo
Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says
2026-08-11 15:05 · Yahoo
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
2026-09-21 17:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.